tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Alliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating
PremiumThe FlyAlliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating
16d ago
Buy Rating Maintained on Aquestive Therapeutics as FDA CRL Seen as Operational Setback with Manageable Risk and Attractive Long‑Term Risk‑Reward
Premium
Ratings
Buy Rating Maintained on Aquestive Therapeutics as FDA CRL Seen as Operational Setback with Manageable Risk and Attractive Long‑Term Risk‑Reward
16d ago
Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval
Premium
The Fly
Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval
16d ago
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
PremiumMarket NewsMorning News Wrap-Up: Friday’s Biggest Stock Market Stories!
1M ago
Midday Fly By: Job growth comes in below forecasts in December
Premium
The Fly
Midday Fly By: Job growth comes in below forecasts in December
1M ago
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
Premium
The Fly
ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James
1M ago
Needle‑Free Anaphylaxis Treatments Poised for Growth: Physician Survey Supports Buy Rating on Aquestive’s Anaphylm (AQST)
PremiumRatingsNeedle‑Free Anaphylaxis Treatments Poised for Growth: Physician Survey Supports Buy Rating on Aquestive’s Anaphylm (AQST)
1M ago
Aquestive Therapeutics management to meet with Oppenheimer
Premium
The Fly
Aquestive Therapeutics management to meet with Oppenheimer
3M ago
Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Approval Prospects and Market Potential
Premium
Ratings
Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Approval Prospects and Market Potential
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100